Back to search

Harokopio University

Nutritional interventions in inflammatory diseases: investigating the molecular pathways

Abstract

dc:description

Inflammation is a biological process against harmful stimuli, such as pathogens, damaged cells and toxic compounds which contributes in infection control and tissue repairing. Inflammatory dysregulation and chronic inflammatory responses may lead to various chronic inflammatory conditions, such as Non-alcoholic fatty liver disease (NAFLD) and Inflammatory Bowel Diseases (IBD). NAFLD is the most common liver disease, characterised by excessive fat accumulation in liver, not caused by alcohol consumption. IBD represents a group of intestinal disorders that are characterized by chronic inflammation of the digestive tract. Both conditions show a high prevalence in Western societies, mainly due to the westernised lifestyle, and are in need for new promising options for treatment with the least side effects. Also, they share common pathogenic features, such as increased intestinal permeability, gut dysbiosis and chronic inflammatory responseMastiha, is a plant product with a plethora of bioactive constituents, such as terpenic acids, phenolic compounds and phytosterols. Mastiha’s anti-inflammatory properties are well established. The aim of this dissertation was to investigate the molecular pathways under which Mastiha exhibits its anti-inflammatory action. More specifically, we explored the effectiveness of Mastiha as a non-pharmacological intervention in both NAFLD and IBD, and which molecular mechanisms accompany this effect.In order to evaluate the effect of Mastiha in NAFLD we designed a multicenter, randomized, double-blinded and placebo-controlled clinical trial and investigated the effect on liver inflammation and fibrosis through MRI, biochemical, inflammatory and multi-omic analyses. After six months of Mastiha supplementation, we observed a significant improvement on microbiota dysbiosis as depicted in Bray-Curtis dissimilarity index which was significantly greater among patients that received Mastiha, compared to Placebo. Also, Mastiha decreased the proportion of Flavonifractor, a taxa involved in the catabolism of quercetin, a flavonoid with antioxidant and anti-inflammatory properties. The above effects paralleled with a decrease in plasma cholic acid and phospholipids, possibly attributed to the bioavailable triterpenic acids of Mastiha. Finally, in severely obese patients we observed an improvement of the liver fibrosis as assessed via MRI. In IBD, we applied a randomized, double-blind, placebo-controlled, parallel-group clinical trial with a 3 months duration for patients in relapse and a 6 months duration in patients for remission. Quantification of inflammatory biomarkers revealed a significant increase of serum interleukin-17A (IL-17A) in the Mastiha group and the different mean changes between Mastiha and placebo groups in inactive patients, with this pattern being observed specifically in Crohn’s disease (CD) patients in remission. Similarly, metabolomics analysis revealed an increase in metabolites, such as the aromatic aminoacids phenylalanine, tyrosine and tryptophan together with alanine, glycine and acetic acid, only in patients in remission. As tryptophan is involved in T-helper-17 regulation, the above suggest a possible shift of Th-17 cells to a more protective pathway in quiescent IBD. Finally, Mastiha regulated some gut microbiota related to inflammatory processes, although no evident effect was observed on microbiota dysbiosis.Taking into account that all the above pointed towards Mastiha’s anti-inflammatory activity, we examined whether this action is attributed to epigenetic mechanisms related to inflammation, such as regulation of miRNA levels. MicroRNAs are small molecules that serve as important regulators of gene expression, including inflammatory pathways. Interestingly, the same microRNA, miR-155 (implicated in lipid and Th-17 regulation) was modified by Mastiha in both clinical trials, revealing a possible common mechanism across Mastiha supplementation in two different inflammatory conditions. More studies are needed to further explore this mode of action and introduce other potential pathways that explain Mastiha’s valuable anti-inflammatory action.

Degree

thesis:*
Grantor dc:publisher
Harokopio University
Year dc:date
2021

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Amerikanou, Charalampia
  • Αμερικάνου, Χαραλαμπία

Subjects

dc:subject × 23

Rights

dc:rights
Statement dc:rights
  • BY_NC_ND_4_0
Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/49555

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Amerikanou, Charalampia; Αμερικάνου, Χαραλαμπία. Nutritional interventions in inflammatory diseases: investigating the molecular pathways. Harokopio University, 2021. http://hdl.handle.net/10442/hedi/49555